Semaglutide Selectively Improves Metabolic and Cognitive Function in 5xFAD Alzheimer's Disease Mice

Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by chronic neuroinflammation, amyloid-beta (Aβ) plaques, and tau tangles, leading to cognitive decline. Current treatments offer limited disease modification. Growing evidence links metabolic syndrome (MetS), insulin resistance (IR), and type 2 diabetes (T2D) to increased AD risk, suggesting metabolic dysfunction often precedes cognitive decline. Targeting shared pathways, such as those influenced by GLP-1 receptor (GLP-1R) agonists, offers a promising therapeutic avenue.

Researchers investigated Semaglutide's effects in 5xFAD mice, a well-established genetic model for Alzheimer's disease. The study aimed to assess improvements in both metabolic and cognitive parameters. They specifically examined markers related to neuronal loss, Aβ deposition, synaptic ultrastructure, and the expression of inflammasome- and pyroptosis-associated proteins. While specific dosing, route, and duration were not detailed in the provided abstract snippet, the focus was on understanding Semaglutide's impact on key aspects of AD pathology.

Semaglutide administration to 5xFAD mice resulted in selective improvements across both metabolic and cognitive function domains. The intervention was associated with attenuation of neuronal loss-related changes, suggesting a protective effect on brain cells. Furthermore, the study observed a significant reduction in Aβ deposition, a hallmark pathological feature of AD.

Semaglutide also improved synaptic ultrastructure, indicating potential restoration of neuronal connectivity and function. Beyond these structural and functional benefits, the researchers found that Semaglutide reduced the AD-associated upregulation of inflammasome- and pyroptosis-associated proteins, highlighting its anti-inflammatory and cell death-inhibiting properties. These findings collectively demonstrate Semaglutide's ability to mitigate multiple facets of AD pathology in this preclinical model, although specific numerical data (e.g., percentages, p-values) were not available in the provided abstract.